-
The company’s first U.S. commercial scale production facility is planned at 200,000 square feet, with possible expansion in the future
-
Once fully operational, the facility’s production capacity will be at least 10,000 metric tons (22 million pounds)
-
The project represents an initial planned investment of $123.35 million in Wilson County, North Carolina
Ryne Biotechnology Wins $4M from CIRM to Develop RNDP-001, an iPSC-Derived Dopamine Neuron Progenitor
February 14, 2023, San Diego, California — Ryne Biotechnology, Inc. (Ryne Bio), a therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological disorders, announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4 million Clinical Stage Research Program (CLIN1) grant. This funding will enable the company to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application within the next 12 months. [Read more…]
Heartseed and Novo Nordisk Dose First Patient with HS-001, an iPSC-Derived Cell Therapy to Treat Heart Failure
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).
Clinical phase 1/2 study (LAPiS Study) will enroll 10 patients with advanced heart failure caused by ischaemic heart disease.
Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. [Read more…]
Growth Rates & Trends within the Cord Blood Industry – Interview with Kenneth Harris
The cord blood banking industry is often surrounded by misleading metrics, making insights from experts especially valuable. In an interview with Kenneth Harris, Chief Advisor for CuraSense Advisors, we delve into his extensive knowledge of the field. The discussion covers global growth rates, key trends shaping the industry, geographic differences in opportunities, and more, providing a comprehensive look at this evolving sector.
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors
FUKUOKA, Japan, and BORDEAUX, France / February 15th, 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells. [Read more…]
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 201
- Next Page »